Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | STAT6 | P42226 | 1/20 | 0.52 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | CDK4 | P11802 | 2/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CCND3 | P30281 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11029599 | 0.88 | MAPKAPK2 (0.58) | SLC2A1EGFRSTAT6MAPKAPK2ADRA2A | |
| SCHEMBL11295065 | 0.85 | STAT6 (0.55) | SLC2A1EGFRSTAT6MAPKAPK2ADRA2A | |
| SCHEMBL11030040 | 0.85 | SLC2A1 (0.51) | SLC2A1EGFRSTAT6MAPKAPK2ADRA2A | |
| SCHEMBL11025081 | 0.85 | STAT6 (0.55) | SLC2A1EGFRSTAT6MAPKAPK2ADRA2A | |
| SCHEMBL11033999 | 0.85 | SLC2A1 (0.51) | SLC2A1EGFRSTAT6MAPKAPK2ADRA2A | |
| SCHEMBL11030049 | 0.85 | SLC2A1 (0.51) | SLC2A1EGFRSTAT6MAPKAPK2ADRA2A | |
| SCHEMBL11030203 | 0.85 | AXL (0.61) | SLC2A1EGFRSTAT6CDK4CDK6 | |
| SCHEMBL11028813 | 0.85 | SLC2A1 (0.53) | SLC2A1EGFRSTAT6MAPKAPK2ADRA2A | |
| SCHEMBL11027974 | 0.84 | SLC2A1 (0.54) | SLC2A1EGFRSTAT6MAPKAPK2ADRA2A | |
| SCHEMBL23080983 | 0.83 | LCK (0.54) | SLC2A1EGFRSTAT6CDK4CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | claimed |
| CN-103380117-A | Picolinamide inhibitors of kinases | ABBOTT LAB | 2013-10-30 | — | — | CN | claimed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | claimed |
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2665711-A1 | PICOLINAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| CN-103380117-A | Picolinamide inhibitors of kinases | ABBOTT LAB | 2013-10-30 | — | — | CN | disclosed |
| WO-2012100135-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ALK, PKN2, ERBB2 | SLC2A1 3662/4885EGFR 44/4885STAT6 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.